Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Gurusamy, Kurinchi Selvan ^a   Sharma, D ^b   Davidson, B R ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CRYOABLATION; CYTOREDUCTIVE SURGERY; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; LIVER METASTASIS; LIVER RESECTION; PALLIATIVE THERAPY; PANCREAS CANCER; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; STOMACH CANCER; TREATMENT OUTCOME;

EID: 44949161196     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007118     Document Type: Review

References (47)

1. Anthony 2002 Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars in Nuclear Medicine 2002;32(2):123-32.
2. Chamberlain 2000 Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al.Hepatic neuroendocrine metastases: does intervention alter outcomes?. Journal of the American College of Surgeons 2000;190(4):432-45.
3. Chung 2001 Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, et al.Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001;130(6):954-62.
4. Coppa 2001 Coppa J, Pulvirenti A, Schiavo M, Romito R, Collini P, Di Bartolomeo M, et al.Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplantation Proceedings 2001;33(1-2):1537-9.
5. DeMets 1987 DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
6. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
7. Egger 1997 Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
8. Faiss 2003 Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al.Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 2003;21(14):2689-96.
9. Falconi 1999 Falconi M, Bassi C, Bonora A, Sartori N, Procacci C, Talamini G, et al.Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumours. Digestive Surgery 1999;16(1):32-8.
10. Fjallskog 2001 Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al.Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92(5):1101-7.
11. Florman 2004 Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al.Liver transplantation for neuroendocrine tumors. Journal of Gastrointestinal Surgery 2004;8(2):208-12.
12. Gluud 2008 Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008, Issue 1. Art. No.: LIVER.
13. Gupta 2005 Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al.Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104(8):1590-602.
14. Henn 2003 Henn AR, Levine EA, McNulty W, Zagoria RJ. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR American Journal of Roentgenology 2003;181(4):1005-10.
15. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
16. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd, 2006.
17. Ito 2003 Ito H, Perez A, Brooks DC, Osteen RT, Zinner MJ, Moore FD Jr, et al.Surgical treatment of small bowel cancer: a 20-year single institution experience. Journal of Gastrointestinal Surgery 2003;7(7):925-30.
18. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reportedmethodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
19. Kolby 2003 Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. The British Journal of Surgery 2003;90(6):687-93.
20. Leotlela 2003 Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocrine-related Cancer 2003;10(4):437-50.
21. Macaskill 2001 Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
22. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported inmeta-analyses?. Lancet 1998;352(9128):609-13.
23. Mukherjee 2001 Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al.Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical Endocrinology 2001;55(1):47-60.
24. NCBI 2006a NCBI. MeSH - Neuroendocrine Tumors. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= mesh&list_uids=68018358&dopt=Full (last accessed on 8 September 2006).
25. NCBI 2006b NCBI. MeSH - Carcinoid Tumor. http: //www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=mesh&list_uids= 68002276&dopt=Full (last accessed on 8 September 2006).
26. NCBI 2006c NCBI. MeSH - Malignant Carcinoid Syndrome. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= mesh&list_uids=68008303&dopt=Full (last accessed on 8 September 2006).
27. NCBI 2006d NCBI. MeSH - Insulinoma. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=mesh&list_uids=68007340&dopt=Full (last accessed on 8 September 2006).
28. NCBI 2006e NCBI. MeSH - Gastrinoma. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?CMD=search&DB=mesh (last accessed on 8 September 2006).
29. NCBI 2006f NCBI. MeSH - Glucagonoma. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?CMD=search&DB=mesh (last accessed on 8 September 2006).
30. NCBI 2006g NCBI. MeSH - Somatostatinoma. http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?CMD=search&DB=mesh (last accessed on 8 Septmeber 2006).
31. NCBI 2006h NCBI. MeSH - Vipoma. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?CMD=search&DB=mesh (last accessed on 8 September 2006).
32. Newell 1992 Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
33. Nguyen 2004 Nguyen C, Faraggi M, Giraudet AL, de Labriolle-Vaylet C, Aparicio T, Rouzet F, et al.Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. Journal of Nuclear Medicine 2004;45(10):1660-8.
34. Oberg 1989 Oberg K, Norheim I, Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. European Journal of Cancer & Clinical Oncology 1989;25(10):1475-9.
35. Osborne 2006 Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al.Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Annals of Surgical Oncology 2006;13(4):572-81.
36. Pasieka 2004 Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004;136(6):1218-26.
37. RevMan 2003 RevMan. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
38. Royle 2003 Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
39. Rubin 1999 Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al.Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 1999;17(2):600-6.
40. Sarmiento 2003 Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 2003;197(1):29-37.
41. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
42. Sheen 2002 Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. The British Journal of Surgery 2002;89(11):1396-401.
43. Sun 2005 Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 2005;23(22):4897-904.
44. Sweeting 2004 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-75.
45. Wangberg 1996 Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, et al.Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World Journal of Surgery 1996;20(7):892-9.
46. Yao 2001 Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al.Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130(4):677-85.
47. Zuetenhorst 2005 Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. The Oncologist 2005;10(2):123-31.